BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang T, Yang JY, Buse JB, Pate V, Tang H, Barnes EL, Sandler RS, Stürmer T. Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease: Real-world Evidence in U.S. Adults.Diabetes Care. 2019;42:2065-2074. [PMID: 31471377 DOI: 10.2337/dc19-0162] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
Number Citing Articles
1 Villumsen M, Schelde AB, Jimenez-Solem E, Jess T, Allin KH. GLP-1 based therapies and disease course of inflammatory bowel disease. EClinicalMedicine 2021;37:100979. [PMID: 34386751 DOI: 10.1016/j.eclinm.2021.100979] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Roy A, Sahoo J, Narayanan N, Merugu C, Kamalanathan S, Naik D. Dipeptidyl peptidase-4 inhibitor-induced autoimmune diseases: Current evidence. World J Diabetes 2021; 12(9): 1426-1441 [PMID: 34630898 DOI: 10.4239/wjd.v12.i9.1426] [Reference Citation Analysis]
3 Huang J, Liu X, Wei Y, Li X, Gao S, Dong L, Rao X, Zhong J. Emerging Role of Dipeptidyl Peptidase-4 in Autoimmune Disease. Front Immunol 2022;13:830863. [DOI: 10.3389/fimmu.2022.830863] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Doni K, Bühn S, Weise A, Mann N, Hess S, Sönnichsen A, Pieper D, Thürmann P, Mathes T. Safety of dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Therapeutic Advances in Drug Safety 2022;13:204209862110723. [DOI: 10.1177/20420986211072383] [Reference Citation Analysis]